Correlation between Receptor Activator of Nuclear Factor-κβ Ligand (RANKL), and Osteoprotegerin (OPG) with Cartilage Degradation in Rheumatoid Arthritis Patients
ABSTRACT: to analyze the
correlation between Receptor activator of nuclear factor-κβ ligand (RANKL),
Osteoprotegrin (OPG) serum level with cartilage oligomeric matrix protein
(COMP) serum level as a marker of cartilage degradation in rheumatoid arthritis
patients. Methods: a cross-sectional study was conducted on the subjects who came
to the outpatient clinic of rheumatology in Cipto Mangunkusumo Hospital.
Patients were diagnosed based on the American College of Rheumatology (ACR)
1987 revised criteria. All numerical data, both primary data and data
transformation were not normally distributed, so we did bivariate analysis with
Spearman correlation test. Results: we collected the data of 60 RA patients
with majority of the subject had active disease activity (78.3%). Methotrexate
was the most widely disease modifying anti-rheumatoid drug (DMARD) used, either
as a single drug (51.7%) or in combination with another DMARD (25.1%).
Bivariate analysis was revealed that RANKL, OPG, and OPG/RANKL serum level have
no signifcantly correlation with COMP serum level (p=0.52; p=0.25; p=0.2,
respectively). Conclusion: RANKL and OPG serum level, had no correlation with
cartilage degradation in rheumatoid arthritis patients.
Author: Rudy Hidayat, Harry
Isbagio, Bambang Setyohadi, Siti Setiati
Journal Code: jpkedokterangg140268
